ChromaDex slips on FDA decision on flagship product ingredient

Niagen Bioscience

11/11/2022 14:29

** Shares of food supplements maker ChromaDex Corp  CDXC.O 
fall as much as 28.3% to $1.32 premarket in volume spike
    ** CDXC says on Nov. 4, U.S. FDA declared that the key
ingredient in the production of company's flagship product Tru
Niagen cannot be sold as a dietary supplement in the U.S.
 urn:newsml:reuters.com:*:nBw5zHhVRa
    ** Company was not immediately available for comment on
impact of the FDA decision on Tru Niagen production
    ** Up to last close, stock down 50.8% YTD
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))